NDANASALSPRAY, METERED
Approved
Aug 1995
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
4/8 — Partial
MIACALCIN (calcitonin salmon) by Viatris is agonist. Approved for symptomatic paget's disease of bone in patients with moderate to severe disease characterized by polyostotic involvement with elevated serum alkaline phosphatase, urinary hydroxyproline excretion, postmenopausal osteoporosis in women greater than 5 years postmenopause and 2 more indications. First approved in 1995.
Drug data last refreshed 2h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
MIACALCIN (calcitonin salmon) is a synthetic peptide hormone agonist administered as a nasal spray that acts on bone, renal, and gastrointestinal tissues to inhibit osteoclast activity and reduce bone resorption. It treats postmenopausal osteoporosis and moderate-to-severe Paget's disease of bone by reducing bone turnover and stabilizing skeletal mass. Calcitonin salmon demonstrates greater potency per mg and longer duration of action than mammalian-origin calcitonins, though its complete role in bone physiology continues to be elucidated.
$0.837MPart D
LOE ApproachingDeclining
Limited expansion opportunity; team likely focused on defending existing patient base and managing transition as loss of exclusivity approaches.
Mechanism of Action
agonist. Calcitonin salmon acts primarily on bone, but direct renal effects and actions on the gastrointestinal tract are also recognized. Calcitonin salmon appears to have actions essentially identical to calcitonins of mammalian origin, but its potency per mg is greater and it has a longer…
Worked on MIACALCIN at Viatris? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.